The overall poor prognosis observed in these patients suggests that the adverse clinical impact of iAMP21 overrides the presumably better prognosis associated with ETV6-RUNX1 in B-ALL. The gene discussed is RUNX1; the disease is precursor B-cell acute lymphoblastic leukemia.